CA2381771A1 - Methods and compositions relating to sodium channel beta1a subunits - Google Patents

Methods and compositions relating to sodium channel beta1a subunits Download PDF

Info

Publication number
CA2381771A1
CA2381771A1 CA002381771A CA2381771A CA2381771A1 CA 2381771 A1 CA2381771 A1 CA 2381771A1 CA 002381771 A CA002381771 A CA 002381771A CA 2381771 A CA2381771 A CA 2381771A CA 2381771 A1 CA2381771 A1 CA 2381771A1
Authority
CA
Canada
Prior art keywords
sodium channel
subunit
cell
beta
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002381771A
Other languages
English (en)
French (fr)
Inventor
Lori L. Isom
Kristin Kazen-Gillespie
Kathryn E. Rogers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Ortho McNeil Pharmaceutical Inc
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc, University of Michigan filed Critical Ortho McNeil Pharmaceutical Inc
Publication of CA2381771A1 publication Critical patent/CA2381771A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
CA002381771A 1999-09-30 2000-09-29 Methods and compositions relating to sodium channel beta1a subunits Abandoned CA2381771A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15683799P 1999-09-30 1999-09-30
US60/156,837 1999-09-30
PCT/US2000/027119 WO2001023571A1 (en) 1999-09-30 2000-09-29 Methods and compositions relating to sodium channel beta1a subunits

Publications (1)

Publication Number Publication Date
CA2381771A1 true CA2381771A1 (en) 2001-04-05

Family

ID=22561303

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002381771A Abandoned CA2381771A1 (en) 1999-09-30 2000-09-29 Methods and compositions relating to sodium channel beta1a subunits

Country Status (5)

Country Link
EP (1) EP1216300A1 (de)
JP (1) JP2003510079A (de)
AU (2) AU7746100A (de)
CA (1) CA2381771A1 (de)
WO (2) WO2001023570A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE368740T1 (de) * 2000-06-07 2007-08-15 Ortho Mcneil Pharm Inc Die menschliche beta-1a-untereinheit des potential-abhängigen natriumkanals und deren verwendungen
US6897319B2 (en) 2001-12-27 2005-05-24 Ortho-Mcneil Pharmaceutical, Inc. Useful aroyl pyrrole heteroaryl methanones and methanols
EP1336847B1 (de) * 2002-02-14 2007-12-12 Biofrontera Pharmaceuticals AG Kathepsin Y Inhibitoren für die Entwicklung von Medikamenten zur Schmerzbehandlung

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU777469B2 (en) * 1999-04-15 2004-10-21 Cambridge University Technical Services Limited A novel family of beta sub-unit proteins from a voltage-gated sodium channel, nucleic acids encoding them and therapeutic or diagnostic uses thereof
WO2000069912A1 (en) * 1999-05-14 2000-11-23 Millennium Pharmaceuticals, Inc. Gene encoding a sodium channel beta-3 subunit protein

Also Published As

Publication number Publication date
JP2003510079A (ja) 2003-03-18
WO2001023570A2 (en) 2001-04-05
WO2001023570A3 (en) 2001-10-25
AU7743500A (en) 2001-04-30
WO2001023571A1 (en) 2001-04-05
EP1216300A1 (de) 2002-06-26
AU7746100A (en) 2001-04-30

Similar Documents

Publication Publication Date Title
US11932908B2 (en) Compositions and methods for diagnosis and treatment of epilepsy
US6790648B2 (en) DNA fragmentation factor involved in apoptosis
US20040260058A1 (en) Novel endothelially expressed dnas and proteins, and their use
US7229816B2 (en) Sitosterolemia susceptibility gene (SSG) polypeptides
CA2381771A1 (en) Methods and compositions relating to sodium channel beta1a subunits
US20050032155A1 (en) Mutation in the beta2 nicotinic acetycholine receptor subunit associated with nocturnal frontal lobe epilepsy
CA2325663A1 (en) Novel mutations in the freac3 gene for diagnosis and prognosis of glaucoma and anterior segment dysgenesis
US20040191791A1 (en) Novel mutation
CA2285631A1 (en) Antioxidant protein 2, gene and methods of use therefor
US20090233986A1 (en) Methods and compositions for using sax2
WO2001016315A1 (fr) Transporteur de choline a forte activite
US20020142417A1 (en) Antioxidant protein 2, gene and methods of use therefor
US20030144205A1 (en) Novel germ cell-specific contraceptive target
US20030082650A1 (en) Great gene and protein
US20060079674A1 (en) Contraceptive targets
US20030118990A1 (en) Novel estrogen-regulated G protein gamma subunit: compositions and methods of use
US20020099190A1 (en) Estrogen-regulated unconventional myosin-related protein: compositions and methods of use
AU2002252833A1 (en) Novel mutation
JP2004121246A (ja) 神経変性疾患の予防・治療剤
WO2001068880A9 (en) Estrogen-regulated myo-inositol phosphate synthase: compositions and methods of use
AU2003228675A1 (en) Contraceptive targets

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20040510